BioTuesdays

Category - Markets

Syros-Logo
Markets

Roth starts Syros at neutral, PT $16

Roth Capital Partners launched coverage of Syros Pharmaceuticals (NASDAQ:SYRS) with a “neutral” rating and price target of $16. The stock closed at $16.51 on Oct.23. “Syros is maturing into a solid company, but value...

October 24, 2017
Markets

Roth resumes coverage of Actinium at buy, PT $6

Roth Capital Partners resumed coverage of Actinium Pharmaceuticals (NYSE American:ATNM) with a “buy” rating and price target of $6.  The stock closed at 73 cents on Oct.23. Analyst Jotin Marango writes that Actinium...

October 24, 2017
GlycoMimetics
Markets

Roth starts GlycoMimetics at buy, PT $25

Roth Capital Partners initiated coverage of GlycoMimetics (NASDAQ:GLYC) with a “buy” rating and $25 price target. The stock closed at $10.52 on Oct. 23. “Our bull thesis on GlycoMimetics is driven by the GMI-1271...

October 24, 2017
Aurinia Pharmaceuticals
Markets

Leerink ups Aurinia price target to $14

Leerink raised its price target for Aurinia Pharmaceuticals (NASDAQ:AUPH) to $14 from $10 after the company’s R&D day in New York last Friday. The stock closed at $6.15 on Oct. 20. Analyst Joseph Schwartz writes...

October 23, 2017
Nightstar Therapeutics
Markets

Leerink starts Nightstar at OP

Leerink initiated coverage of Nightstar Therapeutics (NASDAQ:NITE) with an “outperform” rating and $25 price target. The stock closed at $19 on Oct. 20. Nightstar is harnessing the potentially curative properties of...

October 23, 2017
Gemphire Logo
Markets

Roth starts Gemphire at buy

Roth Capital Markets launched coverage of Gemphire Therapeutics (NASDAQ:GEMP) with a “buy” rating and 12-month price target of $30. The stock closed at $9.54 on Oct. 18. “Our rating on Gemphire is driven by our...

October 19, 2017
Eiger BioPharmaceuticals Logo
Markets

Roth starts Eiger Biopharma at buy

Roth Capital Partners initiated coverage of Eiger Biopharmaceuticals (NASDAQ:EIGR) with a “buy” rating and $35 price target. The stock closed at $11.65 on Oct. 18. Analyst Michael Higgins writes that the company is...

October 19, 2017
Madrigal Pharmaceuticals
Markets

Roth starts Madrigal Pharma at buy

Roth Capital Partners launched coverage of Madrigal Pharmaceuticals (NASDAQ:MDGL) with a “buy” rating and a 12-month price target of $62. The stock closed at $47.52 on Oct. 18. “Our rating on Madrigal shares is based on...

October 19, 2017
Galectin Therapeutics
Markets

Roth starts Galectin at buy

Roth Capital Partners initiated coverage of Galectin Therapeutics (NASDAQ:GALT) with a “buy” rating and a 12-month price target of $8. The stock closed at $2.51 on Oct. 18. “Our rating on Galectin shares is based on our...

October 19, 2017
Ignyta
Markets

Ladenburg ups Ignyta price target to $31

Ladenburg Thalmann raised its price target for Ignyta (NASDAQ:RXDX) to $31 from $20.25 based on expectations for entrectinib to be first line therapy for ROS1+ non-small cell lung cancer (NSCLC). The stock was changing...

October 18, 2017